, and none at 1 3 10 5 cells/well. Based on these facts, a quantitative comparison was carried out between amotosalen/UVA at the highest challenge of 1 3 10 7 PBMCs/well, and gamma irradiation at 1 3 10 6 and 1 3 10 5 PBMCs/well. Complete inactivation of the T cells after amotosalen/UVA treatment was observed, equivalent to greater than 6.2 log inactivation. Complete inactivation of the T cells was also observed after gamma irradiation when 1 3 10 5 PBMCs/ well were cultured (>4.2 log inactivation). Proliferation was observed when 1 3 10 6 PBMCs/well were cultured (5.2 log inactivation) after gamma irradiation.
CONCLUSION: Amotosalen/UVA treatment more effectively inactivates T cells than the current standard of gamma irradiation (2500 cGy) for the prevention of TA-GVHD.
T ransfusion-associated graft-versus-host disease (TA-GVHD) is a highly morbid complication, associated with the transfusion of blood components that contain viable donor T lymphocytes. TA-GVHD was first reported in the 1960s following the transfusion of severely immune-deficient infants and fetuses, 1,2 a few years after GVHD was recognized in animals, and the term was coined. 3 GVHD is well characterized, especially as relating to hematopoietic stem cell transplant, as a disease with different levels of severity and accompanying treatment options. In contrast, the classic description of TA-GVHD is one of a fulminant disease with a rapid onset 2 to 30 days posttransfusion, few treatment options, and high mortality (87%-100%). It is characterized by bone marrow failure (pancytopenia) leading to death from sepsis or other sequelae. 4 Prevention of TA-GVHD is accomplished by using gamma-irradiated blood components for patients at risk; however, identifying such patients is challenging. TA-GVHD was first recognized in patients with varying degrees of immunosuppression, although early instances from Japan 5 and later instances of family donors around the world 6, 7 highlighted that immunocompetent patients may still be susceptible to the disease when their genetic similarity with the donor T cells makes their immune system unable to defend against donor cell attack. 8 In addition, immune suppression may be difficult to predict, as it is affected by factors such as genetic makeup, age, etc., and can be temporarily induced by disease and trauma. A recent review of the literature showed that approximately 60% of TA-GVHD cases followed transfusion of nonirradiated blood components to recipients not identified as being at risk, indicating that treatment of all components may be a better strategy. 9 In the early animal experiments, TA-GVHD was associated with the presence of viable T cells, while in the human cases it was correlated with the transfusion of fresh blood components. 6, 10 In both the animal and the human clinical experience, a correlation between higher lymphocyte doses and the likelihood of disease onset has been observed. 3, [11] [12] [13] There is disagreement over the minimum dose of viable T cells that can cause TA-GVHD, and even though cases associated with doses as low as 8 3 10 4 T cells/kg have been reported, there is enough inconsistency in the literature to make an absolute limit questionable. 14 In modern transfusion medicine, an increased adoption of leukofiltration and the use of stored blood components have led to a marked decrease of the incidence of TA-GVHD, even for nonirradiated components. 15 It is clear, nonetheless, that in addition to limiting the T-cell numbers by leukoreduction techniques such as leukofiltration, additional measures are required in order to protect blood product recipients from TA-GVHD. [15] [16] [17] Gamma irradiation of blood components with doses that abrogate the ability of white blood cells (WBCs) to proliferate is the predominant method to prevent TA-GVHD. In the United States and Europe, only blood components used for the treatment of patients with identified risk require irradiation, while in Japan all components are irradiated. 6, 18 In the United States, doses of 2500 cGy (defined as the dose in the midplane and no less than 1500 cGy in all other points of the irradiation cavity) are recommended to treat blood components 19 for patients identified as at risk for TA-GVHD, while 2500 to 5000 cGy are recommended by the European Directorate for the Quality of Medicines and HealthCare 20 and the British Committee for Standards in Hematology. 21 In Japan, doses of 1500 to 5000 cGy have been used since 1993. 18 The irradiation dose levels recommended evolved as the methodology for the detection of viable T cells improved. Initially, mitogen response and mixed lymphocyte reaction (MLR) were used, but were found to be of limited dynamic range (2-3 log) 12 and were quickly substituted by clonogenic approaches, involving limiting dilution assay (LDA) with larger dynamic ranges (4-5 log). 22 These in vitro assays were correlated and complemented by animal models, where the reduction of viable WBCs to the limit of detection (LOD) coincided with the prevention of TA-GVHD versus untreated positive controls. 23, 24 Preparation of blood components with pathogen reduction methodologies also has been found to be effective against proliferating WBCs, including T cells. [25] [26] [27] [28] [29] Prior studies had demonstrated that amotosalen/ultraviolet A (UVA) is effective in the inactivation of T cells present in platelet components when assessed with a typical LDA, achieving an LOD of approximately 5 log. 25, 29, 30 However, amotosalen/UVA treatment had never been directly compared with gamma irradiation. We designed a T-cell inactivation study to compare the two systems, using an LDA optimized to increase the dynamic range for the detection of T cells that are able to proliferate to 6 to 7 log.
MATERIALS AND METHODS

Study design
The overall investigation comprised a series of rangefinding experiments, a validation phase, and a formal inactivation study performed under good laboratory practices protocol executed at National Jewish Health, designed after discussions with the Food and Drug Administration to support product licensing claims.
Plasma was used as the suspension medium in place of platelets to avoid interference of contaminating platelets with the evaluation of T-cell colonies in the proliferation assay. Platelet clumping in wells limited the LOD in the previous study conducted with platelet components by Grass and colleagues. 25 It has also been recognized that the presence of platelets confounds detection of Tcell colonies due to the formation of platelet aggregates. 29 In addition, platelets may also interfere with the trapping of radioactive thymidine that is not incorporated in nucleic acids of proliferating cells.
Range-finding studies
and concentration of growth factors, the length of culture, the range of live peripheral blood mononuclear cell (PBMC) numbers to achieve meaningful quantitation of T-cell precursors, and the logistics associated with blood product treatment, PBMC isolation, and detection methodologies.
Validation phase
During the validation phase, PBMCs suspended in plasma and treated with either amotosalen/UVA or gamma irradiation were cultured in different culture densities to define numbers that allow reproducible performance of the LDA. In addition, during the validation phase, the culture conditions and appropriate ranges of untreated control PBMCs were defined. The impact of excess inactivated cells on the quantitation of precursor frequency was evaluated, after amotosalen/UVA, or gamma irradiation (2500 cGy) treatments. In three study replicates, equal numbers of live PBMCs added to plasma were cultured (N 5 8 replicate wells) in the presence of either 1 3 10 7 amotosalen/UVAtreated PBMCs or 1 3 10 5 gamma irradiation-treated
PBMCs from the same donor, and compared to T-cell precursor frequency without added inactivated cells, as described in Table S1 (available as supporting information in the online version of this paper).
Inactivation study
For the inactivation study, a plasma pool (950 mL) of ABO-matched plasma components obtained from the Bonfils Blood Center (Denver, CO) was prepared, and split into three identical (approx. 285 mL) components that were then contaminated with PBMCs (1 3 10 6 PBMCs/ . When in routine use, residual amotosalen and photoproducts are reduced after treatment to low levels by exposure to a compound adsorption device (CAD) before transfer of the treated components for storage and release. For this study, the components were treated without exposure to CAD to avoid loss of WBCs. The gamma-irradiated component was treated at the Bonfils Blood Center (Denver, CO) using a ((GAMMA-CELL) 3000 Irradiator, Rad Source), with 2,500 cGy, per the standard operating procedures.
PBMCs from the untreated control component were resuspended in cell culture medium (CCM) and serially diluted for T-cell precursor frequency determination, as described below. For all three treatment groups (untreated, amotosalen-UVA, and gamma irradiated), PBMCs were isolated quantitatively by centrifugation at 900 3 g for 10 minutes and resuspended in CCM for evaluation of T-cell proliferation.
PBMCs were cultured in tissue culture medium, as specified in Table 1 . For the T-cell precursor frequency determination, the untreated control cells were serially diluted, and 1.6 to 50 PBMCs/well were cultured in the presence of allostimulator cells and growth factors (Table 1) .
Each mixture of PBMCs and allostimulators was cultured in 12 replicate wells with a total volume of 4 mL each, in 12-well plates. Plates were cultured in a humidified incubator at 378C/5% CO 2 for 14 days. Every 3 days, the cells were fed by replenishing 1 mL of the media with feeding medium.
The study was performed with 10 replicates, and results were evaluated versus prespecified acceptance criteria: In order for a study replicate to be accepted, the precursor frequency calculations had to be based on more than three evaluable levels of untreated control PBMCs, when both positive and negative replicate wells are observed, and the regression coefficient (r 2 ) was required to be 0.85 or greater.
Evaluation of T-cell proliferation
T-cell growth was evaluated with two methodologies: 1) By visual inspection: T-cell clonal formation on Day 14 was assessed by light microscopy. A well was defined as positive if one or more clones consisting of more than 20 cells were present. 2) By 3 H-thymidine uptake: After 14 days of culture, all wells were pulsed with 3 H-thymidine (150 mCi/well) and incubated for approximately 16 hours. The contents of each well, as well as rinses of the wells, were transferred into multiple wells of a 96-well plate (maximum volume capacity of 200 mL/well) (illustrated in Fig. 1 ). The cells were harvested and 3 H-thymidine incorporation measured. The sum of counts per minute (CPM) corresponding to all wells of the 96-well harvest plates was used as the value for the original well in the 12-well culture plate. The mean and standard deviation (SD) using the average CPM for the background negative control wells were calculated for all dilutions.
A positive well, as determined by 3 H-thymidine uptake, was defined to have a CPM value greater than the cutoff value, defined as the mean of the negative control plus three times the SD of that measurement. The negative control value was the average of 
CALCULATIONS
The T-cell precursor frequencies in the PBMC treatment groups were determined using the CPM data from the untreated control PBMC dilutions according to the formula:
where f is the frequency estimate, x i is the number of untreated control PBMCs added per well, and y i is the natural log of the frequency of negative cultures after x i cell addition. A formula based on single-hit kinetics was used for analysis of this assay because the assay measures only the response from one limiting cell type (T cells in general), and a positive culture can be brought about only by proliferation in response to the allostimulator cells. Log T-cell reduction was calculated separately for each plasma unit by using the following formula:
where f control is the T-cell precursor frequency of the control article, and f test is the T-cell precursor frequency in the test units, when T-cell precursor frequency is expressed as 10 x precursors. For the cases where no growth was observed, a single positive replicate well was assumed in order to calculate the f control . The materials are described in the supporting information, available in the online version of this paper.
RESULTS
During the validation phase, it was found that while the PBMCs treated with amotosalen/UVA could be cultured at a density of 1 3 10 7 cells/well without growth, this was not the case for gamma-irradiated PBMCs cultured at the same density. The growth of the gamma irradiationtreated cells was significant, and cultures collapsed after a week due to overcrowding. Culture of the gamma irradiation-treated PBMCs at lower densities of 1 3 10 5 or 1 3 10 6 cells/well was possible.
In a separate experiment, direct comparison between cultures of gamma-treated (2500 cGy) PBMCs at increasing cell culture density (Fig. 2) showed that significant proliferation was observed for 1 3 10 7 PBMCs/well, some proliferation for 1 3 10 6 PBMCs/well, and no proliferation for 1 3 10 5 PBMCs/well. No proliferation was observed when 33 2500 cGy gamma was used for all cell culture densities (Fig. 2) . Additionally, precursor frequencies were determined (N 5 3) either in cell culture media alone, or in the presence of an excess of inactivated PBMCs, by treatment with amotosalen/UVA, or 7500 cGy gamma irradiation (Table  S1 , available as supporting information in the online version of this paper). The precursor frequencies calculated for all three treatment groups were comparable (Table S2 , available as supporting information in the online version of this paper).
Based on these results, after confirming that inactivated cells did not interfere with T-cell precursor determination, precursor frequencies in the formal inactivation study were determined by culturing untreated control PBMCs in media only, as shown in Table 1 . The study was conducted in 10 replicates, with prespecified acceptance criteria as described in the Materials and Methods section. Eight of 10 study replicates met the prespecified criteria for the determination of na€ ıve T-cell precursor frequency, with each replicate using PBMCs obtained from a unique donor. The two replicates that did not meet these criteria were excluded from the analysis. The general patterns observed, however, were consistent among all 10 replicates.
The precursor frequencies determined from eight replicate evaluations are shown in Table 2 . In addition to the precursor frequencies, culture of the inactivated PBMCs was also conducted in 12 replicate wells, as described in Table 1 . Growth of the T cells was evaluated by Table S3 (available as supporting information in the online version of this paper), and the average values are plotted in Figure 3 . Cutoff values (mean 1 3 SD) for Tcell growth for each replicate were defined from the wells that contained only 5 3 10 6 allostimulator pool cells. The microscopic evaluation of growth was found to be inherently less specific and subjective. However, the results for the two evaluations were compatible with one another, and the calculations of precursor frequencies comparable (data not shown), even though a significant number of wells were found to be false negatives, i.e., negative by microscopic observation but positive by 3 H-thymidine incorporation. The visual assessments for colony growth are shown in Table S3 (available as supporting information in the online version of this paper).
The levels of T-cell inactivation achieved were calculated using the number of PBMCs cultured and the T-cell precursor frequency measured for each PBMC donor, after taking into account the number of tested wells. Overall, INTERCEPT treatment achieved complete inactivation of the T cells when 1 3 10 7 PBMCs were cultured, gamma irradiation achieved complete inactivation of the T cells only when 1 3 10 5 PBMCs were cultured, while gammairradiation did not achieve complete inactivation when 1 3 10 6 PBMCs were cultured. After application of the respective T-cell precursor frequencies, these results indicate that gamma irradiation inactivated more than 4.2 log, but less than 5.2 log of T cells, while INTERCEPT treatment inactivated more than 6.2 log of T cells. The log reduction results are shown in Table 3 and   3 H-thymidine incorporation is shown in Fig. 3 .
Calculation of the inactivation achieved is detailed for Replicate 1 (first row, Table 3 
DISCUSSION
When new methodologies are developed to improve blood safety, they need to be validated for their impact on patient safety and compared with the standard of care. In many cases, this proves to be challenging, as many of the older interventions were established in the absence of a predicate technology and sometimes their use was adjusted as additional data became available. That was the case for the use of gamma irradiation for the prevention of TA-GVHD. Even though it was identified early that gamma irradiation can be effective for the prevention of TA-GVHD, over time the irradiation dose was increased to improve the level of protection for all patient groups identified to be at risk. 19, 30, 31 Technologies developed for the inactivation of pathogens through the modification of nucleic acids also have been found to be effective for the inactivation of WBCs. Studies performed in platelet components have been published with the INTERCEPT Blood System for Platelets using amotosalen/UVA, the (Mirasol system) using riboflavin/UV, and the (Theraflex UVC system) 25, 26, 32 ; for RBC components with the (S-303/GSH system) 27, 33 ; and for whole blood with the riboflavin/UV system. 28, 34 Information is available on the inhibitory effect that various technologies have on MLR and cytokine production, as well as the quantitation of nucleic acid modification after pathogen inactivation treatment. For two technologies (amotosalen/UVA and riboflavin/UV), TA-GVHD prevention was also demonstrated using established animal models. 32, 35 Quantitation of the inactivation of T cells has been reported with all of the technologies listed above using a standard LDA, in some instances in comparison to gamma irradiation. [25] [26] [27] [28] [32] [33] [34] One of these technologies, Early work 36 demonstrated efficient modification of genomic DNA by amotosalen/UVA, in a way that could inhibit amplification of amplicons of more than 300 bp in length. That work was expanded with the demonstration of inhibition of cytokine production from treated leukocytes in stored treated platelet components, indicating inhibition of transcription of DNA and translation of RNA. 37 The effects seen with amotosalen/UVA exceed what is achievable after gamma-irradiation treatment, and are consistent with the difference in the measured levels of nucleic acid modification with the two methodologies (1:37,000 vs. 1:83-1:85 bp for gamma-irradiation vs. amotosalen/UVA). 37, 38 Analysis in previously reported LDA studies showed effective inactivation of T cells to the LOD at more than 5.39 6 0.29 log, 25 and the inactivation of the T cells was further found to be below the LOD, even when the doses of the amotosalen and UVA were reduced by a combined 3000-fold, indicating that at least a 3000-fold level of safety exists for the treatment of blood components for the complete inactivation of T cells. 25, 30, 39 An established parent-to-F1 mouse transfusion model of TA-GVHD was used to show that treatment of splenocytes with amotosalen/UVA prevents TA-GVHD, in a manner similar to a gamma irradiation treatment control and unlike the untreated positive control. 32 In the same study, inactivation of the T cells with amotosalen/ UVA showed inactivation by LDA to the LOD, establishing a correlation between prevention of clinical TA-GVHD and reduction of the T-cell viability below the LOD. 32 The combined data were used for the CE Mark registration for replacement of gamma irradiation with amotosalen/UVA for the prevention of TA-GVHD in 2003. Routine use of the technology since then has resulted in no reported cases of TA-GVHD associated with the transfusion of INTERCEPT-treated platelet (or plasma) components after transfusion of 400,000 components under direct observation through hemovigilance studies or national hemovigilance systems, and no reports to the manufacturer on the transfusion of more than 1.5 million components manufactured for transfusion since the approval of the system for use in lieu of gamma irradiation. 39 This experience was consistent with clinical and postmarketing trial experience where amotosalen/UVAtreated platelet components were used for patient populations at risk. 40, 41 After consideration of the system routine performance and the data above, AABB standards have included the use of amotosalen/UVA as an alternative to gamma since 2015 in the United States. 42 Past studies have shown that gamma irradiation inactivates T cells to the limit of detection, using LDA approaches with similar sensitivity and dynamic range. Given that most inactivation studies are performed at the naturally occurring numbers of WBCs in blood products (approx. 1-2 3 10 6 cells/mL), a critical parameter defining the LOD and thereby the dynamic range of an LDA is the number of WBCs cultured per well. Small-volume wells were exclusively used in the past, allowing the simultaneous culture of a limited WBC number: 5 log per well (Table 4 ). Inactivation to the LOD under these conditions corresponded to inactivation of 4.9 to 5.3 log. When inactivation of T cells with amotosalen/UVA was first tested, a similar assay design was used and comparable inactivation of T cells to the LOD was reported, but a side-by-side comparison with gamma had not been studied until now (Table 4) . A comparison of the ability of the two interventions to inactivate T cells is important to ensure that the two methods are equivalent and would benefit from methodology with maximum sensitivity and dynamic range. In order to increase the dynamic range and LOD of the LDA assay, we have utilized high numbers of PBMCs collected from healthy donors through leukapheresis, and after the respective treatments, we have cultured the cells in larger wells to accommodate their simultaneous expansion in a larger volume. This resulted in the validation of the culture of up to 1 3 10 7 PBMCs in a single well, with the ability to detect and quantify small numbers of proliferating T cells, even in the presence of a vast excess of inactivated PBMCs, by either gamma irradiation or amotosalen/UVA. The ability of cells to proliferate after the two treatments was assessed with both the incorporation of frequencies, we calculated the mean inactivation of T cells achieved by amotosalen/UVA to be more than 6.2 6 0.14 log, while for gamma irradiation the inactivation achieved using this methodology was found to be more than 4.2 6 0.14 log, but equal to or less than 5.2 6 0.14 log (Table 3) . Based on the data obtained in these experiments, it appears that when compared directly, amotosalen/UVA is more effective for the inactivation of T cells than the recommended dose of gamma irradiation for the prevention of TA-GVHD (2500 cGy). These results are consistent with results previously observed (Table 4 ) and the ability to detect proliferation after gamma is due to the higher number of WBCs cultured in a single well.
The significance of detecting residual T cells that are able to proliferate after 2500-cGy gamma irradiation treatment is an area worthy of studying in the context of unreported and/or unrecognized cases of TA-GVHD that may have atypical clinical presentations. 43 
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